🚀 VC round data is live in beta, check it out!
Pyxis Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pyxis Oncology and similar public comparables like Verrica Pharmaceuticals, Laboratorios Richmond, Bioton, Vistin Pharma and more.
Pyxis Oncology Overview
About Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Founded
2018
HQ
Employees
50
Website
Sectors
Financials (LTM)
EV
$52M
Pyxis Oncology Financials
Pyxis Oncology reported last 12-month revenue of $10M.
In the same LTM period, Pyxis Oncology generated $8M in gross profit and had net loss of ($84M).
Revenue (LTM)
Pyxis Oncology P&L
In the most recent fiscal year, Pyxis Oncology reported revenue of $14M and EBITDA of ($80M).
Pyxis Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | $11M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($80M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (577%) | XXX | XXX | XXX |
| EBIT Margin | (880%) | XXX | (608%) | XXX | XXX | XXX |
| Net Profit | ($84M) | XXX | ($80M) | XXX | XXX | XXX |
| Net Margin | (834%) | XXX | (575%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pyxis Oncology Stock Performance
Pyxis Oncology has current market cap of $100M, and enterprise value of $52M.
Market Cap Evolution
Pyxis Oncology's stock price is $1.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $100M | 8.5% | XXX | XXX | XXX | $-1.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPyxis Oncology Valuation Multiples
Pyxis Oncology trades at 5.2x EV/Revenue multiple, and (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Pyxis Oncology Financial Valuation Multiples
As of April 11, 2026, Pyxis Oncology has market cap of $100M and EV of $52M.
Equity research analysts estimate Pyxis Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pyxis Oncology has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.7x) | XXX | XXX | XXX |
| EV/EBIT | (0.6x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | 4.5x | XXX | XXX | XXX |
| P/E | (1.2x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pyxis Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pyxis Oncology Margins & Growth Rates
Pyxis Oncology's revenue in the last 12 month declined by (86%).
Pyxis Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.9M for the same period.
Pyxis Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (86%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (577%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 221% | XXX | 160% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 746% | XXX | 532% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 692% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pyxis Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Verrica Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Richmond | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioton | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| SynAct Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pyxis Oncology M&A Activity
Pyxis Oncology acquired XXX companies to date.
Last acquisition by Pyxis Oncology was on XXXXXXXX, XXXXX. Pyxis Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pyxis Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPyxis Oncology Investment Activity
Pyxis Oncology invested in XXX companies to date.
Pyxis Oncology made its latest investment on XXXXXXXX, XXXXX. Pyxis Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pyxis Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pyxis Oncology
| When was Pyxis Oncology founded? | Pyxis Oncology was founded in 2018. |
| Where is Pyxis Oncology headquartered? | Pyxis Oncology is headquartered in United States. |
| How many employees does Pyxis Oncology have? | As of today, Pyxis Oncology has over 50 employees. |
| Who is the CEO of Pyxis Oncology? | Pyxis Oncology's CEO is Thomas Civik. |
| Is Pyxis Oncology publicly listed? | Yes, Pyxis Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Pyxis Oncology? | Pyxis Oncology trades under PYXS ticker. |
| When did Pyxis Oncology go public? | Pyxis Oncology went public in 2021. |
| Who are competitors of Pyxis Oncology? | Pyxis Oncology main competitors are Verrica Pharmaceuticals, Laboratorios Richmond, Bioton, Vistin Pharma. |
| What is the current market cap of Pyxis Oncology? | Pyxis Oncology's current market cap is $100M. |
| What is the current revenue of Pyxis Oncology? | Pyxis Oncology's last 12 months revenue is $10M. |
| What is the current revenue growth of Pyxis Oncology? | Pyxis Oncology revenue growth (NTM/LTM) is (86%). |
| What is the current EV/Revenue multiple of Pyxis Oncology? | Current revenue multiple of Pyxis Oncology is 5.2x. |
| Is Pyxis Oncology profitable? | No, Pyxis Oncology is not profitable. |
| What is the current net income of Pyxis Oncology? | Pyxis Oncology's last 12 months net income is ($84M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.